Brussels - Delayed Quote EUR

Oxurion NV (OXUR.BR)

0.0799

-0.0060

(-6.98%)

At close: April 25 at 3:43:37 PM GMT+2

Oxurion Share Consolidation

Oxurion Share Consolidation Leuven, BELGIUM – July 25, 2024 – 06:00 PM CET Oxurion NV (Euronext Brussels: OXUR) (the Company), a biopharmaceutical company based in Leuven, announced today that its Board of Directors, authorized by the General Meeting of July 24, 2024, will proceed with a consolidation of all existing shares. This consolidation will be carried out at a ratio of one (1) new share for ten thousand (10,000) existing shares. This share consolidation is a strategic step to increase th

GlobeNewswire 8 months ago

OXUR.BR
-6.98%
Oxurion Announces Results on the Extraordinary General Meeting (EGM) of 24 July 2024

Oxurion Announces Results on the Extraordinary General Meeting (EGM) of 24 July 2024 Leuven, BELGIUM – 24 July, 2024 – 06.00 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, held an Extraordinary General Meeting on July 24, 2024. The shareholders approved all items on the agenda of the Extraordinary General Meeting. All documents pertaining to the Extraordinary General Meeting held on July 24, 2024, can be consulted on Oxurion’s website Oxurion/

GlobeNewswire 8 months ago

OXUR.BR
-6.98%
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas

Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas Atlas Special Opportunities, LLC has converted 4 convertible bonds in Oxurion resulting in a EUR 100,000 capital increase. This is part of Atlas Special Opportunities, LLC’s EUR 20 million Capital Commitment1 that will allow Oxurion to focus on developing innovative therapeutics to preserve the vision of elderly people, targeting potential market opportunities of USD 3-6 billion. Leuven, BELGIUM

GlobeNewswire 9 months ago

OXUR.BR
-6.98%
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC

Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Leuven, BELGIUM – July 18, 2024 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows: Oxurion received a transparency notification on July 17, 2024, from Atlas Special Opportunities, LLC indicating that as of July 17, 2024, it held 941,611,20

GlobeNewswire 9 months ago

OXUR.BR
-6.98%
Oxurion provides clarification on the agenda of the extraordinary general shareholders' meeting to be held on 24 July 2024

Oxurion provides clarification on the agenda of the extraordinary general shareholders' meeting to be held on 24 July 2024 Leuven, BELGIUM – July 11, 2024 – 6:00pm CET – Oxurion NV (Euronext Brussels: OXUR), an innovative biopharmaceutical company based in Leuven, announced today it has provided clarification on the agenda of the extraordinary general shareholders' meeting to be held on 24 July 2024 (the EGM) as set out in the convening notice published on 5 July 2024 in accordance with applicab

GlobeNewswire 9 months ago

OXUR.BR
-6.98%
Oxurion signs a Letter of Intent and enters into exclusive negotiations to potentially acquire a pioneering French CRO in stem cell production

Oxurion signs a Letter of Intent and enters into exclusive negotiations to potentially acquire a pioneering French CRO in stem cell production LEUVEN, BELGIUM - July 8, 2024 – 6:30 pm, Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company based in Leuven, announces that it has signed a Letter of Intent (LOI) to enter into exclusive negotiations with a view to, subject to certain conditions, acquiring an 80% majority stake in a CRO (Contract Research Organisation) operating in a fast-

GlobeNewswire 9 months ago

OXUR.BR
-6.98%
Oxurion announces the results of the Extraordinary General Meeting (EGM) held on 4 July 2024 and convenes a new EGM on 24 July 2024

Oxurion announces the results of the Extraordinary General Meeting (EGM) held on 4 July 2024 and convenes a new EGM on 24 July 2024. Leuven, BELGIUM - 4 July 2024 – 6:00 PM CET, Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company based in Leuven, informs its shareholders and the market that, at today's Extraordinary General Meeting, the attendance quorum required to deliberate and vote on the items on the agenda has not been reached, and that consequently, the Extraordinary General

GlobeNewswire 9 months ago

OXUR.BR
-6.98%
Oxurion Announces Extraordinary General Shareholders’ Meeting

Oxurion Announces Extraordinary General Shareholders’ Meeting Leuven, BELGIUM – June 4, 2024 – 07:00 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, announces an extraordinary general shareholders’ meeting to be held on Thursday July 4, 2024 at 11:00 AM (CET). This extraordinary general shareholders’ meeting regards the proposal of share consolidation in respect of all outstanding shares of the Company by means of a 1-for-10,000 share consolida

GlobeNewswire 10 months ago

OXUR.BR
-6.98%
Oxurion Announces Results on the Annual Shareholders’ Meeting of 16 May 2024

Oxurion Announces Results on the Annual Shareholders’ Meeting of 16 May 2024 Leuven, BELGIUM – 23 May, 2024 – 07.00 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, held its annual shareholders’ meeting on May 16, 2024. The shareholders approved all items on the agenda of the annual shareholders’ meeting. All documents pertaining to the annual shareholders' meeting held on May 16, 2024, can be consulted on Oxurion’s website Oxurion/shareholders.

GlobeNewswire 10 months ago

OXUR.BR
-6.98%
Important Advances in Oxurion's R&D Program on Geographic Atrophy secondary to AMD

` Important Advances in Oxurion's R&D Program on Geographic Atrophy secondary to AMD Leuven, BELGIUM – May 6, 2024 – 6:00 PM CET, Oxurion NV (Euronext Brussels: OXUR), an innovative biopharmaceutical company based in Leuven, today announces important progress in its preclinical program targeting Geographic Atrophy (GA), a severe and underserved form of Age-Related Macular Degeneration (AMD). This recently launched program has reached the first step with the identification of 50 targets that have

GlobeNewswire 11 months ago

OXUR.BR
-6.98%

Performance Overview

Return	OXUR.BR	BEL 20 (^BFX)
YTD	-68.04%	+1.89%
1-Year	-92.01%	+11.62%
3-Year	-100.00%	+4.41%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Oxurion NV (OXUR.BR)

Oxurion Share Consolidation

Oxurion Announces Results on the Extraordinary General Meeting (EGM) of 24 July 2024

Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas

Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC

Oxurion provides clarification on the agenda of the extraordinary general shareholders' meeting to be held on 24 July 2024

Oxurion signs a Letter of Intent and enters into exclusive negotiations to potentially acquire a pioneering French CRO in stem cell production

Oxurion announces the results of the Extraordinary General Meeting (EGM) held on 4 July 2024 and convenes a new EGM on 24 July 2024

Oxurion Announces Extraordinary General Shareholders’ Meeting

Oxurion Announces Results on the Annual Shareholders’ Meeting of 16 May 2024

Important Advances in Oxurion's R&D Program on Geographic Atrophy secondary to AMD

Performance Overview